Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions | Zendy

Lyly Le | Zendy; Kim Chi | Zendy; Scott Tyldesley | Zendy; Stéphane Flibotte | Zendy; Deborah L. Diamond | Zendy; Michael A. Kuzyk | Zendy; Marianne D. Sadar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions

Author(s) -

Lyly Le,

Kim Chi,

Scott Tyldesley,

Stéphane Flibotte,

Deborah L. Diamond,

Michael A. Kuzyk,

Marianne D. Sadar

Publication year - 2005

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2004.041087

Subject(s) - prostate cancer , bone metastasis , biomarker discovery , medicine , biomarker , proteomics , prostate , metastasis , pathology , serum amyloid a , cancer , cancer research , chemistry , biochemistry , inflammation , gene

Prostate cancer has a propensity to metastasize to the bone. Currently, there are no curative treatments for this stage of the disease. Sensitive biomarkers that can be monitored in the blood to indicate the presence or development of bone metastases and/or response to therapies are lacking. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is an affinity-based approach that allows sensitive and high-throughput protein profiling and screening of biological samples.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research